In the WNT pathway, AXIN1 mutations were more frequent in H/L HCC patients (8.7%) compared to NHW patients (3.8%), though the difference did not reach statistical significance (p = 0.12, Table S1). This evidence concerns the gene AXIN1 and hepatocellular carcinoma.